Galactokinase: Difference between revisions
Jump to navigation
Jump to search
m (→Sugar Specificity: Journal cites:, added 3 PMCs using AWB (12151)) |
Matt Pijoan (talk | contribs) m (1 revision imported) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 38: | Line 38: | ||
}} | }} | ||
'''Galactokinase''' is an [[enzyme]] (phosphotransferase) that facilitates the [[phosphorylation]] of [[galactose|α-D-galactose]] to [[galactose 1-phosphate]] at the expense of one [[molecule]] of [[adenosine triphosphate|ATP]].<ref>{{cite web |url=http://www.theodora.com/medical_dictionary/gamma_galactosis.html#galactokinase |title=galactokinase |work=Medical Dictionary |accessdate=2013-01-26}}</ref> Galactokinase catalyzes the second step of the [[Leloir pathway]], a [[metabolic pathway]] found in most [[organisms]] for the [[catabolism]] of β-D-galactose to [[glucose 1-phosphate]].<ref name= "l" /> First isolated from [[mammal]]ian [[liver]], galactokinase has been studied extensively in [[yeast]],<ref name="c1" /><ref name="c2" /> [[archaea]],<ref>{{cite journal| | '''Galactokinase''' is an [[enzyme]] (phosphotransferase) that facilitates the [[phosphorylation]] of [[galactose|α-D-galactose]] to [[galactose 1-phosphate]] at the expense of one [[molecule]] of [[adenosine triphosphate|ATP]].<ref>{{cite web |url=http://www.theodora.com/medical_dictionary/gamma_galactosis.html#galactokinase |title=galactokinase |work=Medical Dictionary |accessdate=2013-01-26}}</ref> Galactokinase catalyzes the second step of the [[Leloir pathway]], a [[metabolic pathway]] found in most [[organisms]] for the [[catabolism]] of β-D-galactose to [[glucose 1-phosphate]].<ref name= "l" /> First isolated from [[mammal]]ian [[liver]], galactokinase has been studied extensively in [[yeast]],<ref name="c1" /><ref name="c2" /> [[archaea]],<ref>{{cite journal | vauthors = Hartley A, Glynn SE, Barynin V, Baker PJ, Sedelnikova SE, Verhees C, de Geus D, van der Oost J, Timson DJ, Reece RJ, Rice DW | title = Substrate specificity and mechanism from the structure of Pyrococcus furiosus galactokinase | journal = Journal of Molecular Biology | volume = 337 | issue = 2 | pages = 387–98 | date = March 2004 | pmid = 15003454 | doi = 10.1016/j.jmb.2004.01.043 }}</ref> [[plants]],<ref>{{cite journal | vauthors = Foglietti MJ, Percheron F | title = [Purification and mechanism of action of a plant galactokinase] | journal = Biochimie | volume = 58 | issue = 5 | pages = 499–504 | year = 1976 | pmid = 182286 | doi = 10.1016/s0300-9084(76)80218-0 }}</ref><ref>{{cite journal | vauthors = Dey PM | title = Galactokinase of Vicia faba seeds | journal = European Journal of Biochemistry | volume = 136 | issue = 1 | pages = 155–9 | date = October 1983 | pmid = 6617655 | doi = 10.1111/j.1432-1033.1983.tb07720.x }}</ref> and [[humans]].<ref name="holden04">{{cite journal | vauthors = Holden HM, Thoden JB, Timson DJ, Reece RJ | title = Galactokinase: structure, function and role in type II galactosemia | journal = Cellular and Molecular Life Sciences | volume = 61 | issue = 19–20 | pages = 2471–84 | date = October 2004 | pmid = 15526155 | doi = 10.1007/s00018-004-4160-6 }}</ref><ref name="meg" /> | ||
==Structure== | ==Structure== | ||
Galactokinase is composed of two domains separated by a large cleft. The two regions are known as the N- and C-terminal domains, and the [[adenine]] ring of ATP binds in a hydrophobic pocket located at their interface. The N-terminal domain is marked by five strands of mixed [[beta-sheet]] and five [[alpha-helices]], and the C-terminal domain is characterized by two layers of anti-parallel beta-sheets and six alpha-helices.<ref name="holden04" /> Galactokinase does not belong to the [[carbohydrate|sugar]] [[kinase]] family, but rather to a class of ATP-dependent enzymes known as the [[GHMP kinase family|GHMP superfamily]].<ref>{{cite journal| | Galactokinase is composed of two domains separated by a large cleft. The two regions are known as the N- and C-terminal domains, and the [[adenine]] ring of ATP binds in a hydrophobic pocket located at their interface. The N-terminal domain is marked by five strands of mixed [[beta-sheet]] and five [[alpha-helices]], and the C-terminal domain is characterized by two layers of anti-parallel beta-sheets and six alpha-helices.<ref name="holden04" /> Galactokinase does not belong to the [[carbohydrate|sugar]] [[kinase]] family, but rather to a class of ATP-dependent enzymes known as the [[GHMP kinase family|GHMP superfamily]].<ref>{{cite journal | vauthors = Tang M, Wierenga K, Elsas LJ, Lai K | title = Molecular and biochemical characterization of human galactokinase and its small molecule inhibitors | journal = Chemico-Biological Interactions | volume = 188 | issue = 3 | pages = 376–85 | date = December 2010 | pmid = 20696150 | pmc = 2980576 | doi = 10.1016/j.cbi.2010.07.025 }}</ref> GHMP is an abbreviation referring to its original members: galactokinase, [[homoserine kinase]], [[mevalonate kinase]], and [[phosphomevalonate kinase]]. Members of the GHMP superfamily have great three-dimensional similarity despite only ten to 20% sequence identity. These enzymes contain three well-conserved motifs (I, II, and III), the second of which is involved in nucleotide binding and has the sequence [[proline|Pro]]-X-X-X-[[glycine|Gly]]-[[leucine|Leu]]-X-[[Serine|Ser]]-Ser-[[alanine|Ala]].<ref name="thoden">{{cite journal | vauthors = Thoden JB, Holden HM | title = Molecular structure of galactokinase | journal = The Journal of Biological Chemistry | volume = 278 | issue = 35 | pages = 33305–11 | date = August 2003 | pmid = 12796487 | doi = 10.1074/jbc.M304789200 }}</ref> | ||
===Sugar | ===Sugar specificity=== | ||
Galactokinases across different species display a great diversity of [[Enzyme#Specificity|substrate specificities]]. ''[[E. coli]]'' galactokinase can also phosphorylate 2-deoxy-D-galactose, 2-amino-deoxy-D-galactose, 3-deoxy-D-galactose and [[fucose|D-fucose]]. The enzyme cannot tolerate any C-4 modifications, but changes at the C-2 position of D-galactose do not interfere with enzyme function.<ref>{{cite journal | vauthors = Yang J, Fu X, Jia Q, Shen J, Biggins JB, Jiang J, Zhao J, Schmidt JJ, Wang PG, Thorson JS | title = Studies on the substrate specificity of Escherichia coli galactokinase | journal = Organic Letters | volume = 5 | issue = 13 | pages = 2223–6 | date = June 2003 | pmid = 12816414 | doi = 10.1021/ol034642d }}</ref> Both human and [[rat]] galactokinases are also able to successfully phosphorylate 2-deoxy-D-galactose.<ref>{{cite journal | vauthors = Timson DJ, Reece RJ | title = Sugar recognition by human galactokinase | journal = BMC Biochemistry | volume = 4 | pages = 16 | date = November 2003 | pmid = 14596685 | pmc = 280648 | doi = 10.1186/1471-2091-4-16 }}</ref><ref>{{cite journal | vauthors = Walker DG, Khan HH | title = Some properties of galactokinase in developing rat liver | journal = The Biochemical Journal | volume = 108 | issue = 2 | pages = 169–75 | date = June 1968 | pmid = 5665881 | pmc = 1198790 }}</ref> Galactokinase from ''[[S. cerevisiae]]'', on the other hand, is highly specific for D-galactose and cannot phosphorylate [[glucose]], [[mannose]], [[arabinose]], fucose, [[lactose]], [[galactitol]], or 2-deoxy-D-galactose.<ref name="c1">{{cite journal | vauthors = Schell MA, Wilson DB | title = Purification of galactokinase mRNA from Saccharomyces cerevisiae by indirect immunoprecipitation | journal = The Journal of Biological Chemistry | volume = 254 | issue = 9 | pages = 3531–6 | date = May 1979 | pmid = 107173 }}</ref><ref name="c2">{{cite journal | vauthors = Sellick CA, Reece RJ | title = Contribution of amino acid side chains to sugar binding specificity in a galactokinase, Gal1p, and a transcriptional inducer, Gal3p | journal = The Journal of Biological Chemistry | volume = 281 | issue = 25 | pages = 17150–5 | date = June 2006 | pmid = 16603548 | doi = 10.1074/jbc.M602086200 }}</ref> Moreover, the kinetic properties of galactokinase also differ across species.<ref name="holden04" /> The sugar specificity of galactokinases from different sources has been dramatically expanded through [[directed evolution]]<ref>{{cite journal | vauthors = Hoffmeister D, Yang J, Liu L, Thorson JS | title = Creation of the first anomeric D/L-sugar kinase by means of directed evolution | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 100 | issue = 23 | pages = 13184–9 | date = November 2003 | pmid = 14612558 | pmc = 263743 | doi = 10.1073/pnas.2235011100 }}</ref> and structure-based [[protein engineering]].<ref>{{cite journal | vauthors = Yang J, Fu X, Liao J, Liu L, Thorson JS | title = Structure-based engineering of E. coli galactokinase as a first step toward in vivo glycorandomization | journal = Chemistry & Biology | volume = 12 | issue = 6 | pages = 657–64 | date = June 2005 | pmid = 15975511 | doi = 10.1016/j.chembiol.2005.04.009 }}</ref><ref>{{cite journal | vauthors = Williams GJ, Gantt RW, Thorson JS | title = The impact of enzyme engineering upon natural product glycodiversification | journal = Current Opinion in Chemical Biology | volume = 12 | issue = 5 | pages = 556–64 | date = October 2008 | pmid = 18678278 | pmc = 4552347 | doi = 10.1016/j.cbpa.2008.07.013 }}</ref> The corresponding broadly permissive sugar anomeric kinases serve as a cornerstone for ''in vitro'' and ''in vivo'' [[glycorandomization]].<ref>{{cite journal | vauthors = Langenhan JM, Griffith BR, Thorson JS | title = Neoglycorandomization and chemoenzymatic glycorandomization: two complementary tools for natural product diversification | journal = Journal of Natural Products | volume = 68 | issue = 11 | pages = 1696–711 | date = November 2005 | pmid = 16309329 | doi = 10.1021/np0502084 }}</ref><ref>{{cite journal | vauthors = Williams GJ, Yang J, Zhang C, Thorson JS | title = Recombinant E. coli prototype strains for in vivo glycorandomization | journal = ACS Chemical Biology | volume = 6 | issue = 1 | pages = 95–100 | date = January 2011 | pmid = 20886903 | pmc = 3025069 | doi = 10.1021/cb100267k }}</ref><ref>{{cite journal | vauthors = Gantt RW, Peltier-Pain P, Thorson JS | title = Enzymatic methods for glyco(diversification/randomization) of drugs and small molecules | journal = Natural Product Reports | volume = 28 | issue = 11 | pages = 1811–53 | date = October 2011 | pmid = 21901218 | doi = 10.1039/c1np00045d }}</ref> | |||
==Mechanism== | ==Mechanism== | ||
Recently, the roles of [[active site]] [[amino acid|residues]] in human galactokinase have become understood. [[aspartic acid|Asp]]-186 abstracts a [[proton]] from C1-OH of α-D-galactose, and the resulting [[alkoxide]] [[nucleophile]] attacks the γ-[[phosphorus]] of ATP. A [[phosphate group]] is transferred to the sugar, and Asp-186 may be [[deprotonation|deprotonated]] by [[water]]. Nearby [[arginine|Arg]]-37 stabilizes Asp-186 in its [[anion]]ic form and has also been proven to be essential to galactokinase function in [[point mutation]] experiments.<ref name="meg">{{cite journal| | Recently, the roles of [[active site]] [[amino acid|residues]] in human galactokinase have become understood. [[aspartic acid|Asp]]-186 abstracts a [[proton]] from C1-OH of α-D-galactose, and the resulting [[alkoxide]] [[nucleophile]] attacks the γ-[[phosphorus]] of ATP. A [[phosphate group]] is transferred to the sugar, and Asp-186 may be [[deprotonation|deprotonated]] by [[water]]. Nearby [[arginine|Arg]]-37 stabilizes Asp-186 in its [[anion]]ic form and has also been proven to be essential to galactokinase function in [[point mutation]] experiments.<ref name="meg">{{cite journal | vauthors = Megarity CF, Huang M, Warnock C, Timson DJ | title = The role of the active site residues in human galactokinase: implications for the mechanisms of GHMP kinases | journal = Bioorganic Chemistry | volume = 39 | issue = 3 | pages = 120–6 | date = June 2011 | pmid = | doi = 10.1016/j.bioorg.2011.03.001 }}</ref> Both the aspartic acid and arginine active site residues are highly [[conserved sequence|conserved]] among galactokinases.<ref name="holden04" /> | ||
[[Image:Galactokinase mechanism1.png|thumb|none|500px| The likely galactokinase mechanism.<ref name="meg" /> The aspartate residue is stabilized in its anionic form by a nearby arginine residue.]] | [[Image:Galactokinase mechanism1.png|thumb|none|500px| The likely galactokinase mechanism.<ref name="meg" /> The aspartate residue is stabilized in its anionic form by a nearby arginine residue.]] | ||
[[File:Galactokinase crystal structure.png|thumb|right| Crystal structure of galactokinase active site from ''Lactococcus lactis. ''<ref name="thoden" /> Galactokinase is shown in green, phosphate in orange, and the residues responsible for binding the sugar ligand are shown in magenta: Arg-36, Glu-42, Asp-45, Asp-183, and Tyr-233. Arg-36 and Asp-183 of ''Lactococcus lactis'' galactokinase are analogous to Arg-37 and Asp-186 in human galactokinase. (From {{PDB|1PIE}})]] | [[File:Galactokinase crystal structure.png|thumb|right| Crystal structure of galactokinase active site from ''Lactococcus lactis.''<ref name="thoden" /> Galactokinase is shown in green, phosphate in orange, and the residues responsible for binding the sugar ligand are shown in magenta: Arg-36, Glu-42, Asp-45, Asp-183, and Tyr-233. Arg-36 and Asp-183 of ''Lactococcus lactis'' galactokinase are analogous to Arg-37 and Asp-186 in human galactokinase. (From {{PDB|1PIE}})]] | ||
==Biological | ==Biological function== | ||
The Leloir pathway catalyzes the conversion of galactose to glucose. Galactose is found in [[dairy products]], as well as in [[fruits]] and [[vegetables]], and can be produced endogenously in the breakdown of [[glycoproteins]] and [[glycolipids]]. Three enzymes are required in the Leloir pathway: galactokinase, [[galactose-1-phosphate uridylyltransferase]], and UDP-galactose 4-epimerase. Galactokinase catalyzes the first committed step of galactose catabolism, forming galactose 1-phosphate.<ref name= "l" /><ref>{{cite journal| | The Leloir pathway catalyzes the conversion of galactose to glucose. Galactose is found in [[dairy products]], as well as in [[fruits]] and [[vegetables]], and can be produced endogenously in the breakdown of [[glycoproteins]] and [[glycolipids]]. Three enzymes are required in the Leloir pathway: galactokinase, [[galactose-1-phosphate uridylyltransferase]], and UDP-galactose 4-epimerase. Galactokinase catalyzes the first committed step of galactose catabolism, forming galactose 1-phosphate.<ref name= "l" /><ref>{{cite journal | vauthors = Holden HM, Rayment I, Thoden JB | title = Structure and function of enzymes of the Leloir pathway for galactose metabolism | journal = The Journal of Biological Chemistry | volume = 278 | issue = 45 | pages = 43885–8 | date = November 2003 | pmid = 12923184 | doi = 10.1074/jbc.R300025200 }}</ref> | ||
==Disease | ==Disease relevance== | ||
[[Galactosemia]], a rare [[metabolic disorder]] characterized by decreased ability to metabolize galactose, can be caused by a mutation in any of the three enzymes in the Leloir pathway.<ref name= "l">{{cite journal| | [[Galactosemia]], a rare [[metabolic disorder]] characterized by decreased ability to metabolize galactose, can be caused by a mutation in any of the three enzymes in the Leloir pathway.<ref name= "l">{{cite journal | vauthors = Frey PA | title = The Leloir pathway: a mechanistic imperative for three enzymes to change the stereochemical configuration of a single carbon in galactose | journal = FASEB Journal | volume = 10 | issue = 4 | pages = 461–70 | date = March 1996 | pmid = 8647345 }}</ref> [[Galactokinase deficiency]], also known as galactosemia type II, is a [[recessive gene|recessive]] metabolic disorder caused by a [[mutation]] in human galactokinase. About 20 mutations have been identified that cause galactosemia type II, the main [[symptom]] of which is early onset [[cataracts]]. In [[lens (anatomy)|lens]] [[cell (biology)|cells]] of the human [[eye]], [[aldose reductase]] converts galactose to galactitol. As galactose is not being catabolized to glucose due to a galactokinase mutation, galactitol accumulates. This galactitol gradient across the lens cell membrane triggers the [[osmosis|osmotic]] uptake of water, and the swelling and eventual [[apoptosis]] of lens cells ensues.<ref>{{cite journal | vauthors = Timson DJ, Reece RJ | title = Functional analysis of disease-causing mutations in human galactokinase | journal = European Journal of Biochemistry | volume = 270 | issue = 8 | pages = 1767–74 | date = April 2003 | pmid = 12694189 | doi = 10.1046/j.1432-1033.2003.03538.x }}</ref> | ||
| doi = 10.1046/j.1432-1033.2003.03538.x | |||
==References== | == References == | ||
{{Reflist}} | {{Reflist}} | ||
==External links== | == External links == | ||
* {{MeshName|Galactokinase}} | * {{MeshName|Galactokinase}} | ||
Latest revision as of 12:36, 9 January 2019
| Galactokinase 1 | |
|---|---|
| File:Galactokinase 1 1WUU.png | |
| Identifiers | |
| Symbol | GALK1 |
| Alt. symbols | GALK |
| Entrez | 2584 |
| HUGO | 4118 |
| OMIM | 604313 |
| RefSeq | NM_000154 |
| UniProt | P51570 |
| Other data | |
| EC number | 2.7.1.6 |
| Locus | Chr. 17 q23-q25 |
| Galactokinase 2 | |
|---|---|
| Identifiers | |
| Symbol | GALK2 |
| Entrez | 2585 |
| HUGO | 4119 |
| OMIM | 137028 |
| RefSeq | NM_002044 |
| UniProt | Q01415 |
| Other data | |
| EC number | 2.7.1.6 |
| Locus | Chr. 15 [1] |
Galactokinase is an enzyme (phosphotransferase) that facilitates the phosphorylation of α-D-galactose to galactose 1-phosphate at the expense of one molecule of ATP.[1] Galactokinase catalyzes the second step of the Leloir pathway, a metabolic pathway found in most organisms for the catabolism of β-D-galactose to glucose 1-phosphate.[2] First isolated from mammalian liver, galactokinase has been studied extensively in yeast,[3][4] archaea,[5] plants,[6][7] and humans.[8][9]
Structure
Galactokinase is composed of two domains separated by a large cleft. The two regions are known as the N- and C-terminal domains, and the adenine ring of ATP binds in a hydrophobic pocket located at their interface. The N-terminal domain is marked by five strands of mixed beta-sheet and five alpha-helices, and the C-terminal domain is characterized by two layers of anti-parallel beta-sheets and six alpha-helices.[8] Galactokinase does not belong to the sugar kinase family, but rather to a class of ATP-dependent enzymes known as the GHMP superfamily.[10] GHMP is an abbreviation referring to its original members: galactokinase, homoserine kinase, mevalonate kinase, and phosphomevalonate kinase. Members of the GHMP superfamily have great three-dimensional similarity despite only ten to 20% sequence identity. These enzymes contain three well-conserved motifs (I, II, and III), the second of which is involved in nucleotide binding and has the sequence Pro-X-X-X-Gly-Leu-X-Ser-Ser-Ala.[11]
Sugar specificity
Galactokinases across different species display a great diversity of substrate specificities. E. coli galactokinase can also phosphorylate 2-deoxy-D-galactose, 2-amino-deoxy-D-galactose, 3-deoxy-D-galactose and D-fucose. The enzyme cannot tolerate any C-4 modifications, but changes at the C-2 position of D-galactose do not interfere with enzyme function.[12] Both human and rat galactokinases are also able to successfully phosphorylate 2-deoxy-D-galactose.[13][14] Galactokinase from S. cerevisiae, on the other hand, is highly specific for D-galactose and cannot phosphorylate glucose, mannose, arabinose, fucose, lactose, galactitol, or 2-deoxy-D-galactose.[3][4] Moreover, the kinetic properties of galactokinase also differ across species.[8] The sugar specificity of galactokinases from different sources has been dramatically expanded through directed evolution[15] and structure-based protein engineering.[16][17] The corresponding broadly permissive sugar anomeric kinases serve as a cornerstone for in vitro and in vivo glycorandomization.[18][19][20]
Mechanism
Recently, the roles of active site residues in human galactokinase have become understood. Asp-186 abstracts a proton from C1-OH of α-D-galactose, and the resulting alkoxide nucleophile attacks the γ-phosphorus of ATP. A phosphate group is transferred to the sugar, and Asp-186 may be deprotonated by water. Nearby Arg-37 stabilizes Asp-186 in its anionic form and has also been proven to be essential to galactokinase function in point mutation experiments.[9] Both the aspartic acid and arginine active site residues are highly conserved among galactokinases.[8]
Biological function
The Leloir pathway catalyzes the conversion of galactose to glucose. Galactose is found in dairy products, as well as in fruits and vegetables, and can be produced endogenously in the breakdown of glycoproteins and glycolipids. Three enzymes are required in the Leloir pathway: galactokinase, galactose-1-phosphate uridylyltransferase, and UDP-galactose 4-epimerase. Galactokinase catalyzes the first committed step of galactose catabolism, forming galactose 1-phosphate.[2][21]
Disease relevance
Galactosemia, a rare metabolic disorder characterized by decreased ability to metabolize galactose, can be caused by a mutation in any of the three enzymes in the Leloir pathway.[2] Galactokinase deficiency, also known as galactosemia type II, is a recessive metabolic disorder caused by a mutation in human galactokinase. About 20 mutations have been identified that cause galactosemia type II, the main symptom of which is early onset cataracts. In lens cells of the human eye, aldose reductase converts galactose to galactitol. As galactose is not being catabolized to glucose due to a galactokinase mutation, galactitol accumulates. This galactitol gradient across the lens cell membrane triggers the osmotic uptake of water, and the swelling and eventual apoptosis of lens cells ensues.[22]
References
- ↑ "galactokinase". Medical Dictionary. Retrieved 2013-01-26.
- ↑ 2.0 2.1 2.2 Frey PA (March 1996). "The Leloir pathway: a mechanistic imperative for three enzymes to change the stereochemical configuration of a single carbon in galactose". FASEB Journal. 10 (4): 461–70. PMID 8647345.
- ↑ 3.0 3.1 Schell MA, Wilson DB (May 1979). "Purification of galactokinase mRNA from Saccharomyces cerevisiae by indirect immunoprecipitation". The Journal of Biological Chemistry. 254 (9): 3531–6. PMID 107173.
- ↑ 4.0 4.1 Sellick CA, Reece RJ (June 2006). "Contribution of amino acid side chains to sugar binding specificity in a galactokinase, Gal1p, and a transcriptional inducer, Gal3p". The Journal of Biological Chemistry. 281 (25): 17150–5. doi:10.1074/jbc.M602086200. PMID 16603548.
- ↑ Hartley A, Glynn SE, Barynin V, Baker PJ, Sedelnikova SE, Verhees C, de Geus D, van der Oost J, Timson DJ, Reece RJ, Rice DW (March 2004). "Substrate specificity and mechanism from the structure of Pyrococcus furiosus galactokinase". Journal of Molecular Biology. 337 (2): 387–98. doi:10.1016/j.jmb.2004.01.043. PMID 15003454.
- ↑ Foglietti MJ, Percheron F (1976). "[Purification and mechanism of action of a plant galactokinase]". Biochimie. 58 (5): 499–504. doi:10.1016/s0300-9084(76)80218-0. PMID 182286.
- ↑ Dey PM (October 1983). "Galactokinase of Vicia faba seeds". European Journal of Biochemistry. 136 (1): 155–9. doi:10.1111/j.1432-1033.1983.tb07720.x. PMID 6617655.
- ↑ 8.0 8.1 8.2 8.3 Holden HM, Thoden JB, Timson DJ, Reece RJ (October 2004). "Galactokinase: structure, function and role in type II galactosemia". Cellular and Molecular Life Sciences. 61 (19–20): 2471–84. doi:10.1007/s00018-004-4160-6. PMID 15526155.
- ↑ 9.0 9.1 9.2 Megarity CF, Huang M, Warnock C, Timson DJ (June 2011). "The role of the active site residues in human galactokinase: implications for the mechanisms of GHMP kinases". Bioorganic Chemistry. 39 (3): 120–6. doi:10.1016/j.bioorg.2011.03.001.
- ↑ Tang M, Wierenga K, Elsas LJ, Lai K (December 2010). "Molecular and biochemical characterization of human galactokinase and its small molecule inhibitors". Chemico-Biological Interactions. 188 (3): 376–85. doi:10.1016/j.cbi.2010.07.025. PMC 2980576. PMID 20696150.
- ↑ 11.0 11.1 Thoden JB, Holden HM (August 2003). "Molecular structure of galactokinase". The Journal of Biological Chemistry. 278 (35): 33305–11. doi:10.1074/jbc.M304789200. PMID 12796487.
- ↑ Yang J, Fu X, Jia Q, Shen J, Biggins JB, Jiang J, Zhao J, Schmidt JJ, Wang PG, Thorson JS (June 2003). "Studies on the substrate specificity of Escherichia coli galactokinase". Organic Letters. 5 (13): 2223–6. doi:10.1021/ol034642d. PMID 12816414.
- ↑ Timson DJ, Reece RJ (November 2003). "Sugar recognition by human galactokinase". BMC Biochemistry. 4: 16. doi:10.1186/1471-2091-4-16. PMC 280648. PMID 14596685.
- ↑ Walker DG, Khan HH (June 1968). "Some properties of galactokinase in developing rat liver". The Biochemical Journal. 108 (2): 169–75. PMC 1198790. PMID 5665881.
- ↑ Hoffmeister D, Yang J, Liu L, Thorson JS (November 2003). "Creation of the first anomeric D/L-sugar kinase by means of directed evolution". Proceedings of the National Academy of Sciences of the United States of America. 100 (23): 13184–9. doi:10.1073/pnas.2235011100. PMC 263743. PMID 14612558.
- ↑ Yang J, Fu X, Liao J, Liu L, Thorson JS (June 2005). "Structure-based engineering of E. coli galactokinase as a first step toward in vivo glycorandomization". Chemistry & Biology. 12 (6): 657–64. doi:10.1016/j.chembiol.2005.04.009. PMID 15975511.
- ↑ Williams GJ, Gantt RW, Thorson JS (October 2008). "The impact of enzyme engineering upon natural product glycodiversification". Current Opinion in Chemical Biology. 12 (5): 556–64. doi:10.1016/j.cbpa.2008.07.013. PMC 4552347. PMID 18678278.
- ↑ Langenhan JM, Griffith BR, Thorson JS (November 2005). "Neoglycorandomization and chemoenzymatic glycorandomization: two complementary tools for natural product diversification". Journal of Natural Products. 68 (11): 1696–711. doi:10.1021/np0502084. PMID 16309329.
- ↑ Williams GJ, Yang J, Zhang C, Thorson JS (January 2011). "Recombinant E. coli prototype strains for in vivo glycorandomization". ACS Chemical Biology. 6 (1): 95–100. doi:10.1021/cb100267k. PMC 3025069. PMID 20886903.
- ↑ Gantt RW, Peltier-Pain P, Thorson JS (October 2011). "Enzymatic methods for glyco(diversification/randomization) of drugs and small molecules". Natural Product Reports. 28 (11): 1811–53. doi:10.1039/c1np00045d. PMID 21901218.
- ↑ Holden HM, Rayment I, Thoden JB (November 2003). "Structure and function of enzymes of the Leloir pathway for galactose metabolism". The Journal of Biological Chemistry. 278 (45): 43885–8. doi:10.1074/jbc.R300025200. PMID 12923184.
- ↑ Timson DJ, Reece RJ (April 2003). "Functional analysis of disease-causing mutations in human galactokinase". European Journal of Biochemistry. 270 (8): 1767–74. doi:10.1046/j.1432-1033.2003.03538.x. PMID 12694189.
External links
- Galactokinase at the US National Library of Medicine Medical Subject Headings (MeSH)